Search clinical trials for: tapentadol (CG5503) ER 25-mg TRF

Total 30 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Low Back Pain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants

Healthy

United States
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Arthritis | Joint Diseases | Osteoarthritis
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Pain | Lower Back Pain | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Canada
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Low Back Pain
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Pain | Osteoarthritis | Low Back Pain

United States, Australia, Canada, New Zealand
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Healthy
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

Healthy

United States
Thai Red Cross AIDS Research Centre

Recruiting

Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men

Drug Interaction

Thailand
Yonsei University

Unknown

Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resistance

Hepatitis B | Antiviral Drug Adverse Reaction
Grünenthal GmbH

Completed

Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women

Prolonged QTc Interval | Pharmacokinetic

Germany
Sandoz

Completed

To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions

Depression
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Pain | Knee Osteoarthritis

Austria, Croatia, Germany, Hungary, Italy, Latvia, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, United Kingdom
Fundacion SEIMC-GESIDA

Active, not recruiting

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (MAFALDA-R)

HIV Infections | Fatty Liver Disease

Spain
National Institute of Allergy and Infectious Diseases...

Terminated

Emtricitabine/Tenofovir Alafenamide as Salvage ART

HIV

United States
Taichung Veterans General Hospital
Institute of Adherence to Medication

Recruiting

Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection

Safety Issues

Taiwan
Spanish Clinical Pharmacology Society
Spanish reumatology Society

Completed

Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF (REDES-TNF)

Spondylarthropathies

Spain
State University of New York at Buffalo
Gilead Sciences

Active, not recruiting

Bictegravir in the Elderly Living With HIV (BICEP)

HIV-1-infection

United States
Hospital Italiano de Buenos Aires
Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious...

Unknown

TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)

COVID-19 | Healthcare Workers | SARS-CoV 2

Argentina
Johnson & Johnson Pte Ltd

Terminated

A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (RISE)

Human Immunodeficiency Virus Infections

India
Saniona

Completed

Study to Investigate the Pharmacokinetic Profile

Healthy Male Subjects

Germany
Xiayun He, MD

Completed

Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
University of California, San Francisco
Boston University; Boston Medical Center; Mbarara University of Science and Technology

Completed

Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) (ADEPTT)

HIV/AIDS | Tuberculosis | Alcohol Abuse

Uganda
ViiV Healthcare
GlaxoSmithKline

Completed

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Canada

3

Subscribe